<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43711">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02125825</url>
  </required_header>
  <id_info>
    <org_study_id>KinesiaDPhaseIIYear1</org_study_id>
    <secondary_id>9R44AG044293</secondary_id>
    <nct_id>NCT02125825</nct_id>
  </id_info>
  <brief_title>Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration</brief_title>
  <acronym>Kinesia-D</acronym>
  <official_title>Kinesia-D Phase II In-Clinic Continuous Assessment Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Great Lakes NeuroTechnologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Great Lakes NeuroTechnologies Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to assess a compact, portable, wireless movement disorder system with
      continuous monitoring capabilities to detect and quantify the severity of levodopa-induced
      dyskinesia in Parkinson's disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Correlation between motion sensor features and clinician-rated dyskinesia severity</measure>
    <time_frame>All data will be collected within a single session not to exceed 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Motor function (movement speed and magnitude measured with a motion sensor) will be collected for a period of 2 hours after taking normally prescribed dose of levodopa.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson's disease on levodopa</arm_group_label>
    <description>Individuals with Parkinson's disease who are taking levodopa to treat motor symptoms</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with Parkinson's disease and a history of levodopa-induced dyskinesia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic Parkinson's disease

          -  Clinical history of levodopa-induced dyskinesia

          -  21 Years of age or older

          -  Stage 2 - 4 OFF-medication on the Hoehn and Yahr scale

        Exclusion Criteria:

          -  Dementia (determined by a neuropsychological assessment)

          -  Severe tremor unaffected by levodopa
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Pulliam, PhD</last_name>
    <phone>2163615410</phone>
    <email>cpulliam@glneurotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Zoltan Mari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michelle Burack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>April 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
